Next-Gen Nanobodies With MoonLake's Jorge Santos Da Silva, Ph.D.
Business Of Biotech
00:00
The Rise and Fall of the SPAC Deal
George Santos: We are the first ever clinical trial to try a primary endpoint at 75% of improvement. There's a big catalyst also coming now in March, all our competitors read their their HS data. So lots of reads in the in these indications this year. And certainly we'll will be very much looking forward to to our success throughout 23 and then we'll see what we do next back to your previous question.
Transcript
Play full episode
